Envoy Medical, Inc. (COCH): Nasdaq/NYSE listing notice — Envoy Medical gets Nasdaq extension until Feb 23, 2026 to meet listing requirement

Envoy Medical, Inc.

Nasdaq panel grants exception until Feb 23, 2026 to comply with $35M market value listing rule.
Company cites recent equity raises, debt extinguishment, and FDA approval of final stage of Acclaim cochlear implant trial.
Over 28 million shares outstanding; trading volume increased since trial expansion announcement.
Company must promptly notify Nasdaq of any events affecting compliance during the exception period.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Envoy Medical, Inc. received a nasdaq extension granted notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

October 23, 2025, the Nasdaq Hearings Panel (the “Panel”) notified Envoy Medical, Inc. (the “Company) that it has granted the Company’s request for an exception to demonstrate compliance with the $35 million market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”) for continued listing through February 23, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events that occur, including any event that may call into question the

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Envoy Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-102828

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.